Theravance Could Face Prospect Of Another Trial For Vibativ In HAP
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Theravance could potentially have to conduct a new clinical trial to gain FDA approval for a nosocomial pneumonia indication for the firm's antibiotic Vibativ
You may also be interested in...
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.